Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98.6M
-
Number of holders
-
71
-
Total 13F shares, excl. options
-
30.1M
-
Shares change
-
-539K
-
Total reported value, excl. options
-
$200M
-
Value change
-
-$13.2M
-
Put/Call ratio
-
0
-
Number of buys
-
44
-
Number of sells
-
-37
-
Price
-
$6.66
Significant Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q4 2021
92 filings reported holding SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q4 2021.
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 71 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.1M shares
of 98.6M outstanding shares and own 30.54% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (8.74M shares), FMR LLC (3.75M shares), Nextech Invest AG (1.91M shares), WASATCH ADVISORS INC (1.77M shares), RA CAPITAL MANAGEMENT, L.P. (1.74M shares), BlackRock Inc. (1.58M shares), MORGAN STANLEY (1.39M shares), VANGUARD GROUP INC (1.31M shares), EcoR1 Capital, LLC (1.06M shares), and Nantahala Capital Management, LLC (1.01M shares).
This table shows the top 71 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.